RU2016143875A3 - - Google Patents

Download PDF

Info

Publication number
RU2016143875A3
RU2016143875A3 RU2016143875A RU2016143875A RU2016143875A3 RU 2016143875 A3 RU2016143875 A3 RU 2016143875A3 RU 2016143875 A RU2016143875 A RU 2016143875A RU 2016143875 A RU2016143875 A RU 2016143875A RU 2016143875 A3 RU2016143875 A3 RU 2016143875A3
Authority
RU
Russia
Application number
RU2016143875A
Other languages
Russian (ru)
Other versions
RU2702101C2 (ru
RU2016143875A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016143875A publication Critical patent/RU2016143875A/ru
Publication of RU2016143875A3 publication Critical patent/RU2016143875A3/ru
Application granted granted Critical
Publication of RU2702101C2 publication Critical patent/RU2702101C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2016143875A 2014-07-09 2015-07-09 Способ лечения двигательных расстройств бефирадолом RU2702101C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462022462P 2014-07-09 2014-07-09
US62/022,462 2014-07-09
PCT/EP2015/065763 WO2016005527A1 (en) 2014-07-09 2015-07-09 A method for treating movement disorders with befiradol

Publications (3)

Publication Number Publication Date
RU2016143875A RU2016143875A (ru) 2018-08-10
RU2016143875A3 true RU2016143875A3 (pt-PT) 2019-02-01
RU2702101C2 RU2702101C2 (ru) 2019-10-04

Family

ID=53682662

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016143875A RU2702101C2 (ru) 2014-07-09 2015-07-09 Способ лечения двигательных расстройств бефирадолом

Country Status (16)

Country Link
US (3) US10548885B2 (pt-PT)
EP (1) EP3131549B1 (pt-PT)
JP (2) JP6636458B2 (pt-PT)
KR (1) KR102533428B1 (pt-PT)
CN (1) CN106456622B (pt-PT)
AU (1) AU2015286675B2 (pt-PT)
CA (1) CA2946829C (pt-PT)
DK (1) DK3131549T3 (pt-PT)
ES (1) ES2668379T3 (pt-PT)
HU (1) HUE037945T2 (pt-PT)
MX (1) MX2016014740A (pt-PT)
PL (1) PL3131549T3 (pt-PT)
PT (1) PT3131549T (pt-PT)
RU (1) RU2702101C2 (pt-PT)
WO (1) WO2016005527A1 (pt-PT)
ZA (1) ZA201607419B (pt-PT)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10548885B2 (en) * 2014-07-09 2020-02-04 Pierre Fabre Medicament Method for treating movement disorders with befiradol
US10626105B2 (en) 2016-09-22 2020-04-21 Auspex Pharmaceuticals, Inc. Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds
PL3664787T3 (pl) 2017-07-20 2022-10-24 Neurolixis Zastosowanie selektywnych agonistów receptora serotoninowego 5-HT1A do leczenia skutków ubocznych inhibitorów VMAT

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
FR2755967B1 (fr) 1996-11-21 1999-01-29 Pf Medicament Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
US6060345A (en) * 1997-04-21 2000-05-09 Advanced Micro Devices, Inc. Method of making NMOS and PMOS devices with reduced masking steps
FR2820743B1 (fr) 2001-02-09 2005-02-25 Pf Medicament Procede et intermediaires de synthese pour la preparation de derives de pyridin-2-yl-methylamine
JP5053846B2 (ja) * 2004-08-12 2012-10-24 クエスト ファーマシューティカル サーヴィシーズ 生物活性化合物の制御放出送達用医薬組成物
US7040843B1 (en) 2005-03-17 2006-05-09 Great Lakes Custom Tool Mfg., Inc. Flooring hollow back relief cutting tool and method
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
WO2011008546A2 (en) * 2009-06-29 2011-01-20 Capricorn Pharma, Inc. Solid and semi-solid dosage forms and systems and methods for forming and packaging thereof
US8912192B2 (en) 2010-02-12 2014-12-16 Taisho Pharmaceutical Co., Ltd Extended release preparation
US20120076865A1 (en) * 2010-03-24 2012-03-29 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
WO2012030314A1 (en) * 2010-09-01 2012-03-08 Mithridion, Inc. Compositions comprising 5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine, and methods of administering same
HUE031661T2 (en) 2010-10-15 2017-07-28 Contera Pharma Aps Combinations of serotonin receptor agonists for the treatment of movement disorders
US20140243350A1 (en) * 2011-07-05 2014-08-28 Contera Pharma Aps Use of serotonin receptor agonists for treatment of movement disorders
US10561618B2 (en) * 2012-04-18 2020-02-18 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
US10548885B2 (en) * 2014-07-09 2020-02-04 Pierre Fabre Medicament Method for treating movement disorders with befiradol

Also Published As

Publication number Publication date
WO2016005527A1 (en) 2016-01-14
RU2702101C2 (ru) 2019-10-04
BR112016026648A2 (pt) 2017-08-15
RU2016143875A (ru) 2018-08-10
JP2018138568A (ja) 2018-09-06
HUE037945T2 (hu) 2018-09-28
US10548885B2 (en) 2020-02-04
PT3131549T (pt) 2018-07-04
JP6636458B2 (ja) 2020-01-29
KR102533428B1 (ko) 2023-05-16
JP2017524651A (ja) 2017-08-31
EP3131549B1 (en) 2018-03-28
BR112016026648A8 (pt) 2021-07-20
US20210338646A1 (en) 2021-11-04
DK3131549T3 (en) 2018-05-28
US20170239231A1 (en) 2017-08-24
AU2015286675A1 (en) 2016-11-24
JP6824924B2 (ja) 2021-02-03
KR20170029407A (ko) 2017-03-15
ZA201607419B (en) 2023-12-20
US20200138800A1 (en) 2020-05-07
CN106456622A (zh) 2017-02-22
PL3131549T3 (pl) 2018-09-28
US11090298B2 (en) 2021-08-17
EP3131549A1 (en) 2017-02-22
CN106456622B (zh) 2020-05-19
CA2946829A1 (en) 2016-01-14
ES2668379T3 (es) 2018-05-17
AU2015286675B2 (en) 2017-08-24
CA2946829C (en) 2018-05-22
MX2016014740A (es) 2017-03-06

Similar Documents

Publication Publication Date Title
BR112016023095A2 (pt-PT)
BR112016019084A2 (pt-PT)
BR112016018935A2 (pt-PT)
BR112016016536A2 (pt-PT)
BR112016015519A2 (pt-PT)
BR112016017429A2 (pt-PT)
BR112016019575A2 (pt-PT)
BR112016017337A2 (pt-PT)
BR112016019573A2 (pt-PT)
BR112016020096A2 (pt-PT)
BR112016018468A2 (pt-PT)
BR112016021745A2 (pt-PT)
BR112016020587A2 (pt-PT)
BR112016015642A2 (pt-PT)
BR112016020335A2 (pt-PT)
BR112016026882A2 (pt-PT)
BR112016020595A2 (pt-PT)
BR112014024551A2 (pt-PT)
BR112016001204A2 (pt-PT)
BR112016026459A2 (pt-PT)
BR112016021052A2 (pt-PT)
BR112016017033A2 (pt-PT)
BR112016015896A2 (pt-PT)
RU2015146214A3 (pt-PT)
RU2016143875A3 (pt-PT)